Morgan Stanley Crypto Trading Ambitions Drawing Nearer: Bloomberg

Wall Street bank Morgan Stanley (MS) is moving deeper into digital assets, announcing a partnership with crypto infrastructure provider Zerohash to allow E*Trade clients to trade bitcoin , ether (ETH) and solana starting in the first half of 2026, Bloomberg reported on Tuesday.

Jed Finn, Morgan Stanley’s head of wealth management, told Bloomberg that the initiative is the first phase of a broader crypto strategy that will eventually include a full wallet solution.

STORY CONTINUES BELOW
Don’t miss another story.Subscribe to the Crypto Daybook Americas Newsletter today. See all newsletters

“The underlying technology has been proven and blockchain-based infrastructure is obviously here to stay,” Finn said in the interview, adding that clients should have access to both traditional and digital assets in a single ecosystem.

The move underscores Wall Street’s growing embrace of crypto since a regulatory shift under President Donald Trump earlier this year.

Morgan Stanley is also preparing an asset-allocation framework for clients that will include crypto exposure ranging from zero to a few percentage points, depending on investor goals.

The bank is exploring tokenization for back-office efficiencies such as settlement and clearing, the article said.

E*Trade is is an online brokerage and banking platform owned by Morgan Stanley. It allows customers to trade stocks, bonds, exchange-traded funds (ETFs), and options.

Read more: Morgan Stanley Eyes Launching Crypto Trading Through E*Trade: Bloomberg

spot_img

Related Articles

Corporate Clients Hold Up to 15% of Assets on Mercado Bitcoin,...

Corporate clients, mainly small and medium enterprises, account for between 10% and 15% of all assets under custody on Mercado...
Read more
MGX, a fund backed by Dubai’s ruling family, will take a 15% stake in TikTok’s U.S. business as part of...
Crypto markets modestly bounced on Friday with BTC$109,810.41 back above $110,000. Ethereum's ETH$4,048.13 outperformed with a 3.8% gain to cross...